Could a quick Beta-Blocker shot save more heart muscle?

NCT ID NCT07293832

Recruiting now Knowledge-focused Sponsor: Aristotle University Of Thessaloniki Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving the beta-blocker landiolol early, during a heart attack, can reduce the amount of heart muscle that dies. It will follow 100 patients who get either landiolol or a standard oral beta-blocker, based on their doctor's choice. The main goal is to measure heart damage with an MRI three months later.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: landiolol (a cardio-selective beta-blocker)
What this could lead to: If results are promising, it could suggest that early landiolol use helps limit heart muscle damage after a heart attack.
What could go wrong: This is an observational study, not a randomized trial, so results may be influenced by patient differences. The study is small (100 people) and early, so findings may not be conclusive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEMI are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STEMI

Contacts and locations

Locations

Hippokration General Hospital of Thessaloniki
RECRUITING

Thessaloniki, Thessaloniki, 546 42, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.